Klivira
Request demo

Streamlining Cigna Xarelto Prior Authorization Workflows

Klivira automates the complex process of Cigna Xarelto prior authorization, ensuring that rivaroxaban, a critical direct oral anticoagulant, moves through the Evernorth Express Scripts system efficiently.

Revenue cycle directors and prior authorization coordinators face significant challenges managing pharmacy benefit PAs for high-volume medications like Xarelto. Understanding Cigna Healthcare's specific requirements, submission channels, and policy nuances is crucial to minimize delays and improve patient access to essential therapies for conditions such as atrial fibrillation and VTE.

Understanding Cigna Xarelto Prior Authorization Requirements

Xarelto (rivaroxaban) is a direct oral anticoagulant (DOAC) prescribed for indications such as atrial fibrillation and venous thromboembolism (VTE). Cigna Healthcare's formulary typically places rivaroxaban on a tier that may necessitate prior authorization, often including step therapy requirements where a trial of alternative therapies is required before approval.

Navigating Cigna's Submission Channels for Rivaroxaban

For pharmacy benefit medications like Xarelto, Cigna Healthcare partners with Evernorth's Express Scripts as its PBM. Prior authorization requests for rivaroxaban are primarily routed through Express Scripts' provider PA system or via established ePA partners such as CoverMyMeds and Surescripts for prescriber-initiated workflows. This ensures direct electronic submission from the point of care.

Key Policy Considerations for Xarelto with Cigna Healthcare

Cigna Healthcare publishes specific medical necessity guidelines and coverage policies for DOACs on its provider site, CignaforHCP.com. These policies outline clinical criteria for Xarelto approval, often detailing required diagnoses, previous treatment failures for step therapy, and contraindications. Reviewing the latest policy versions is essential for accurate submission.

Expediting Xarelto PA Decisions with Klivira's Automation

Klivira integrates directly with EMR systems to extract necessary clinical data and automates the submission of Cigna Xarelto prior authorization requests to Evernorth's Express Scripts and its ePA partners. This streamlines the process, reduces manual data entry, and helps ensure that all required documentation for rivaroxaban is included for a timely review.

Common Denial Reasons and Appeal Pathways for Xarelto with Cigna

  • Medical necessity not met or insufficient clinical documentation.
  • Failure to meet step therapy requirements as outlined in Cigna's policy.
  • Non-formulary pharmacy denial through Express Scripts.
  • Benefit exclusion or site-of-service mismatch (less common for retail pharmacy).
  • Appeal pathways are documented on CignaforHCP.com and include peer-to-peer review options for clinical denials.

Adhering to Cigna Prior Authorization Turnaround Times

Cigna Healthcare's prior authorization turnaround times for Xarelto are governed by state insurance regulations for commercial plans. For Medicare Advantage and Qualified Health Plans on the FFM, Cigna is an impacted payer under CMS-0057-F, which mandates 72-hour standard and 24-hour expedited PA timeframes. Klivira helps track these crucial deadlines.

Frequently asked questions

What are the typical Cigna Xarelto prior authorization requirements?

Cigna Healthcare typically requires prior authorization for Xarelto (rivaroxaban) based on specific clinical indications like atrial fibrillation or VTE, often incorporating step therapy. This means documentation of a trial with a preferred alternative or a contraindication to it may be necessary before Xarelto is approved. Detailed criteria are found in Cigna's coverage policies.

How is Xarelto prior authorization submitted to Cigna?

For pharmacy benefit drugs like Xarelto, prior authorizations are submitted to Evernorth's Express Scripts, Cigna's PBM. Submissions can be made directly through the Express Scripts provider portal or electronically via ePA partners such as CoverMyMeds and Surescripts, which integrate with many EMR systems.

What are common reasons for Cigna Xarelto PA denials?

Common denial reasons for Xarelto PA with Cigna Healthcare include insufficient documentation to support medical necessity, failure to meet step therapy requirements as outlined in their policies, or issues related to the Express Scripts formulary. Klivira's platform helps proactively identify and mitigate these common denial patterns.

How can Klivira help with Cigna Xarelto prior authorizations?

Klivira streamlines Cigna Xarelto prior authorization by integrating with your EMR to automatically extract patient data and clinical notes. Our platform then facilitates electronic submission to Evernorth's Express Scripts and its ePA partners, reducing manual effort, improving data accuracy, and helping to accelerate approval times for rivaroxaban.

Does Cigna require step therapy for Xarelto (rivaroxaban)?

Yes, Cigna Healthcare's coverage policies for Xarelto (rivaroxaban) often include step therapy requirements. This means that patients may need to try and fail on a preferred, often generic, direct oral anticoagulant or demonstrate a clinical reason for not using it before Xarelto is approved. Always check the current Cigna policy for specific details.

Related coverage

Other xarelto prior authorization by payer

Other xarelto prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo